Literature DB >> 19174811

Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis.

Changcheng Wang1, Yuhong Yuan, Richard H Hunt.   

Abstract

OBJECTIVES: The majority of distal esophageal adenocarcinomas are believed to arise in patients with Barrett's esophagus (BE). Helicobacter pylori (H. pylori) infection plays an etiological role in gastric carcinogenesis, but any possible role in BE is uncertain. We aimed to explore the possible relationship between H. pylori infection and BE by meta-analysis.
METHODS: Observational studies comparing the prevalence of H. pylori infection in patients with BE and healthy controls conducted in adult populations and published in all languages were identified through MEDLINE, EMBASE, and Cochrane database searches up to week 5, 2008. H. pylori infection had to be confirmed by histology and/or serology and/or RUT and/or culture. Studies were excluded if no raw data for outcomes of interest were available or controls were patients with disease or duplicate publications. Summary effect size was calculated as odds ratio (OR) and 95% confidence intervals (CIs) by the random-effects model using Review Manager 4.2.8.
RESULTS: Of 519 citations identified, a total of 12 case-control studies compared the prevalence of H. pylori infection in BE (n=550) and controls (9 studies included controls with normal endoscopy and 3 studies used healthy blood donors as control, n=2,979). There was no significant difference in the overall prevalence of H. pylori infection between BE and controls (42.9% vs. 43.9%, OR=0.74, 95% CI 0.40-1.37, P=0.34), but with significant heterogeneity. Subgroup analysis showed that the prevalence of H. pylori infection was significantly lower in BE than in endoscopically normal healthy controls (23.1% vs. 42.7%, OR=0.50, 95% CI 0.27-0.93, P=0.03) with significant heterogeneity observed between studies. The heterogeneity was eliminated by excluding a single Asian outlier study. In contrast, H. pylori infection was significantly increased in BE patients in the three studies using healthy blood donors as "normal controls" (71.2% vs. 48.1%, OR=2.21, 95% CI 1.07-4.55). In BE patients, the prevalence of H. pylori infection was significantly lower in the esophagus than in the stomach (3.3% vs. 24.7%, OR=0.14, 0.03-0.67) in three studies.
CONCLUSIONS: H. pylori infection and BE are inversely related when compared with endoscopically normal controls but not blood donor controls. Limited evidence suggests that there is no clear association between H. pylori infection and BE. To determine more accurately the effect size of H. pylori infection in BE, high quality prospective case-control studies with age-matched, endoscopically normal healthy controls are needed.

Entities:  

Mesh:

Year:  2009        PMID: 19174811     DOI: 10.1038/ajg.2008.37

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  26 in total

Review 1.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

2.  Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study.

Authors:  Aaron P Thrift; Nirmala Pandeya; Kylie J Smith; Adèle C Green; Nicholas K Hayward; Penelope M Webb; David C Whiteman
Journal:  Int J Cancer       Date:  2011-08-17       Impact factor: 7.396

3.  Reply to letter to the editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First).

Authors:  Sri Ganeshamurthy Thrumurthy; Christopher John Lewis; Susan Pritchard; Gordon Armstrong; Stephen Edwin Arthur Attwood
Journal:  Surg Endosc       Date:  2012-01       Impact factor: 4.584

4.  Risk factors associated with Barrett's epithelial dysplasia.

Authors:  Mikiko Fujita; Yuri Nakamura; Saeko Kasashima; Maiko Furukawa; Ryoichi Misaka; Hikaru Nagahara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 5.  The impact of proton pump inhibitors on the human gastrointestinal microbiome.

Authors:  Daniel E Freedberg; Benjamin Lebwohl; Julian A Abrams
Journal:  Clin Lab Med       Date:  2014-09-24       Impact factor: 1.935

6.  Carcinogenesis of Barrett's esophagus: a review of the clinical literature.

Authors:  Jiro Watari; Tadayuki Oshima; Hirokazu Fukui; Toshihiko Tomita; Hiroto Miwa
Journal:  Clin J Gastroenterol       Date:  2013-08-14

7.  IRAK-M modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells.

Authors:  Tyler S Cole; Min Zhang; Theodore J Standiford; Michael Newstead; Jay Luther; Jiajie Zhang; Chun-Chia Chen; John Y Kao
Journal:  Immunol Lett       Date:  2012-03-28       Impact factor: 3.685

8.  Association between Helicobacter pylori and Barrett's esophagus: a case-control study.

Authors:  Lori A Fischbach; David Y Graham; Jennifer R Kramer; Massimo Rugge; Gordana Verstovsek; Paola Parente; Abeer Alsarraj; Stephanie Fitzgerald; Yasser Shaib; Neena S Abraham; Anna Kolpachi; Swapna Gupta; Marcelo F Vela; Maria Velez; Rhonda Cole; Bhupinderjit Anand; Hashem B El Serag
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

Review 9.  Barrett's oesophagus: frequency and prediction of dysplasia and cancer.

Authors:  Gary W Falk
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-01-20       Impact factor: 3.043

10.  Advances in gastric cancer prevention.

Authors:  Antonio Giordano; Letizia Cito
Journal:  World J Clin Oncol       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.